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Cocaine was considered incapable of producing dependence in 1980 but was proclaimed the
"drug of greatest national public health concern" by 1984. Clinical consensus in 1980 held that
cocaine did not produce a withdrawal syndrome, but recent clinical investigations demonstrate
that cocaine produces unique abuse and withdrawal patterns that differ from other major abused
drugs. Evolving pre-clinical research over the past twodecades now suggests that chronic cocaine
abuse produces neurophysiological alterations in specific central nervous system systems that
regulate the capacity to experience pleasure. These evolving clinical and pre-clinical constructs
have led to applications of promising experimental pharmacological treatments for cocaine
abuse.
In 1980, cocaine was considered a benign euphoriant [1,2]. Cocaine's popularity was
increasing, but broad distribution of cocaine began only in the late 1970s, and little
time had elapsed to allow the development of extreme cocaine abuse, so cocaine
abusers rarely appeared seeking treatment. By 1982, cocaine abusers had begun to
appear at the Substance Abuse Treatment Unit ofYale University and the Addiction
Prevention and Treatment Foundation, and the authors founded the Yale cocaine
abuse treatmentand research program when the number ofprimary cocaineabusers in
the treatment unit reached four (the average census is now over 60 cocaine abusers).
The establishment of a unit devoted to cocaine dependence led to a continuing,
systematic research effort that has advanced new conceptualizations of cocaine
dependence and of the appropriateness of pharmacologic treatment strategies. This
article reviews the recent evolution ofour understanding ofcocaine dependence.
EVOLUTION OF CLINICAL UNDERSTANDING
In 1980, the Comprehensive Textbook ofPsychiatry stated that "taken no more
than two or three times per week, cocaine creates no serious problems" [1]. The
Diagnostic and Statistical Manual-III (DSM-III) of the American Psychiatric
Association reflected the prevailing perception that withdrawal or tolerance to cocaine
did not occur and the Manual did not list cocaine dependence as a substance abuse
problem [3]. Case reports of cocaine dependence from the turn of the century were
considered aberrant exaggerations. Experts claimed that cocaine produced, at worst,
"minor psychological disturbances" and "psychological" addiction only in some
addiction-prone abusers (reviewed in [4]). Moreover, this psychological addiction was
considered a relatively minor clinical condition amenable to treatment with psycho-
therapy, in contrast to the "physiological" addiction associated with narcotics, alcohol,
and sedative-hypnotics.
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This clinical consensus existed despite the fact that systematic clinical studies of
cocaine abusers had not occurred. Our initial clinical studies were intended, therefore,
to reconcile thedisparity between the clinical wisdom ofthe time, that cocaine was not
supposed to produce true addiction, and the fact that it was being cited increasingly by
patients as the direct cause ofcompulsive drug taking and seeking treatment.
We employed direct clinical observation of subjects in treatment, using semi-
structured interviews as well as structured assessments of cocaine craving and use.
These studies showed that cocaine produced a dependence similar, in magnitude and
resistance to treatment, to other drugs of abuse such as alcohol and opiates, but that
cocaine dependence differed substantially in the pattern ofabuse development and in
clinical presentation.
Four areas of clinical importance were targeted by these initial investigations: (1)
details ofthe progression ofdyscontrol over cocaine use [5], (2) patterns ofcocaine use
[6], (3) abstinence symptomatology [7], and (4) the role played by co-morbid
psychiatric disorders [7,8]. Most of these initial observations took place in a very
carefully followed subsample of 30 cocaine abusers who were treated between 1982
and 1984. Details ofsample characteristics appear elsewhere [6,7,9].
The Progression to Cocaine Dependence[5,l11
Our cocaine abusers related that, as in earlier descriptions of the developing
amphetamine dependence [10], dyscontrol over cocaine useoccurredgradually, within
a social context. Initally, low cocaine doses enhance social enjoyment or vocational
performance [5,11]. Few negative consequences of such use were initally apparent;
however, lengthening episodes of use, sleep disruption, dosage escalation, and
increased social isolation all gradually become accompaniments ofcocaine use. Two to
five years usually elapsed between initial exposure to cocaine and treatment seeking,
explaining the lag between cocaine's initial popularization and the latterappearanceof
reports of addiction. Compulsive, uncontrolled, binge use began when availability
increased (e.g., increased funds, improved supply sources, engaging in cocaine
commerce), or on a switch to an administration route of higher intensity, which
delivered increased doses to the brain (smoking or intravenous route). The extreme
euphoria produced by such binges produced vivid memories that formed the founda-
tion for later stimulant craving.
The human cocaine addicts we studied described binges thatparalleled the repeated
rapid cocaine self-administration observed in animals provided unlimited access
(reviewed in [12]). Thoughts of loved ones, safety, responsibilities, and morality did
not enter consciousness during binges. Only thoughts ofstimulant effects and supplies
persisted. While a similar gradual progression to dyscontrol has been described for
other abused drugs, such as opiates and alcohol, the time course for dependence has
generally been longer [13], and simpleavailability oflarge amountsoftheabuseddrug
played a less central role, especially in alcohol abuse, than in cocaine abusers.
Public misconception in 1982 often held that intranasal cocaine did not cause
addiction; however, 50 percent of the abusers studied were exclusive intranasal users,
debunking this perception. Theclinical presentation ofintranasal abusersdid not differ
from that ofother abusers, with the same severity ofdependence [6].
Patterns ofCocaine Use in Dependence[6]
Continuous, daily useofalcohol oropiates isconsidered the normal pattern in opiate
or alcohol dependence. Use isgenerallyrepeated within a dayofthe last use, in order to
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ameliorate rapidly appearing withdrawal symptoms. Because many cocaine abusers
did not use cocaine daily, the absence of a daily use pattern was considered evidence
that cocaine produced a less severe and intractable addiction. While many of the
cocaine users we studied described daily use within the year preceding seeking
treatment, over 90 percent described a transition to binge abuse on developing
dyscontrol. The binge pattern became more pronounced as attempts to curtail use were
initiated, and several extra days ofabstinence moreoften separated binges. Bythetime
of treatment seeking, users averaged one to three binges per week, lasting from 8-24
hours. Counterintuitively, abusers described that their earlier daily use was associated
with some control over cocaine intake-use could be stopped while cocaine supplies
remained in order to allow normal sleep to occur. When dyscontrol occurred, users
were unable to refrain until supplies were exhausted, and usethroughout the night took
place, resulting in prolonged binges followed by intervals ofabstinence. This observa-
tion established that the absence of a daily use pattern in a cocaine abuser did not
indicate decreased impairment, and often indicated the opposite, providing a crucial
clinical distinction between cocaine addiction and alcohol or opiate dependence.
It should be noted that a pattern of unceasing cocaine bingeing, as described
previously by Seigel [14] also occurred, but in less than 10 percent of the sample. In
such abuse, brief periods (three to six hours) ofsleep interrupt continuous, long-term,
high-dose intake [14], but this pattern required almost unlimited access to cocaine
(> $100,000/year cocaine expense).
Abstinence Symptoms [7]
We observed a tri-phasic cocaine abstinence pattern that helped dispel the percep-
tion that cocaine use produces no withdrawal. The three phases are summarized
below.
Crash (Phase 1): Other investigators had emphasized an immediate post-cocaine
depression following a binge [14,15]. This "crash" of mood and energy was also
described by our patients immediately after cessation of a cocaine binge. Cocaine
craving, depression, agitation, and anxiety rapidly intensified. We were intrigued,
however, by descriptions that, over approximately one to four hours, cocaine craving
was supplanted by mounting fatigue and craving for sleep; further use is then often
strongly rejected, unlike parallel points after several hours of opiate, sedative, or
alcohol withdrawal. The cocaine abusers administered alcohol, anxiolytics, sedatives,
opiates, or marijuana to induce sleep. Once sleep occurred, prolonged hypersomno-
lence followed. The "crash's" length was related to the duration and intensity of the
preceding binge. The exhaustion, depression, and hypersomnolence of the crash
probably reflect acute neurotransmitter depletion caused by the preceding cocaine
binge [16]. Clinical recovery from the "crash" in part depends on sleep, diet, and
probably time for neurotransmitter synthesis and repletion. Usual management
included nutrition and rest. When the abuser awakens from the hypersomnolence, few
crash residua persisted, and the offset of the crash is therefore self-limited.
The crash had sometimes been confused with withdrawal from cocaine by prior
investigators [14,17,18]. This confusion had resulted in the erroneous perceptions that
(1) withdrawal symptoms ended with resolution of the crash; (2) no withdrawal
treatment was needed, since the crash was self-limited; and (3) withdrawal symptoms
in cocaine abuse were intense but short. Other investigators questioned whether the
crash was even a withdrawal equivalent. Instead they considered it an acute reaction to
the massive stimulation of the cocaine binge, concluding that no neurophysiological
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adaptation to cocaine occurred and that therefore no withdrawal treatment was
necessary [19]. We hypothesized instead that the crash was like the acute withdrawal
ofthe alcohol "hangover" [7,20] and concurred that it does not contribute to long-term
abuse. Because of the striking consistency of several-day intervals between cocaine
binges, however, we then further evaluated whether other withdrawal symptoms with
delayed emergence might be present.
Withdrawal (Phase 2): The usual manifestations of physiological withdrawal
symptoms (e.g., hypertension, tachycardia, diaphoresis, piloerection, seizures, cramps)
that are produced by abused drugs such as opiates or alcohol are absent in cocaine
abusers, which led to the belief that cocaine's addiction was purely "psychological."
We observed the gradual onset of a significant protracted dysphoric syndrome,
including decreased activation, amotivation, and intense boredom with limited plea-
sure from the environment (anhedonia), after a variable, brief (one to five days)
euthymic interval following the crash. These subtle psychological symptoms were less
dramatic than those of the crash and went unrecognized by most early observers. We
observed no gross physiological alterations. The symptoms were generally not constant
or severe enough to meet psychiatric diagnostic criteria for major mood disorders. Such
symptoms nonetheless frequently led to resumption of cocaine use and repetition of a
cyclical pattern: binge-crash-euthymic interval-anhedonia-relapse-binge.
Of additional importance was our observation that abusers were often able to
withstand the anhedonia of this phase until confronted with classically conditioned
cues that evoked memories of cocaine euphoria. Conditioned cocaine cravings were
cued by varied, idiosyncratic objects or events that had been temporally paired with
cocaine euphoria. Cues included specific persons, locations, or events (e.g., birthdays),
or seeing abuse objects (e.g., money, glass pipes, mirrors, syringes, and single-edged
razor blades, among many others). Internal cues also evoked craving (e.g., mild alcohol
intoxication, or mood states, such as anxiety caused by interpersonal strife which the
user had previously soothed by cocaine). When compared to the limited ability to
experience pleasure during cocaine withdrawal, cues evoked vivid memories ofextreme
euphoria, inducing severe stimulant craving, and hence resumption of use. Once
abstinence was sustained, however, anhedonic symptoms lifted within two to ten
weeks.
Because the anhedonic state was directly related to craving and resumption ofuse, it
paralleled "withdrawal" from other abused substances, except for the absence ofgross
physiological changes, and we thus termed it cocaine "withdrawal." As with other
drugs of abuse, the withdrawal syndrome from cocaine was an inversion ofacute drug
effects. Cocaine acutely amplifies normal pleasure to produce exaggerated euphoria;
cocaine chronically produces a withdrawal state of dampened euphoric response to
produce anhedonia. The concordance of these symptoms with several types of data on
neurophysiological and behavioral alterations after chronic stimulants in animals
(reviewed below), and to pharmacotherapy effects (also reviewed below) led us to
conceptualize this state as a plausiblepsychologicalmanifestation ofneuroadaptation
to chronicperturbation ofbrain reward systems by cocaine, and hence to hypothesize
that its origins were physiological despite its primarily psychological symptom
expression.
Extinction (Phase 3): Despite resolution of the craving related to withdrawal
anhedonia, intermittent cocaine craving was reported to recur by long-abstinent
cocaine abusers based on cued memories of cocaine euphoria. As we followed our
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sample over time, craving based on conditioned cues was reported months or even years
after last cocaine use. The craving was episodic, lasting only hours. Lasting recovery
from cocaine dependence appeared to depend on experiencing this intermittent
conditioned craving without relapsing. The previous pairing of cues with euphoria
would notoccur, and, as expected in a classical conditioning phenomenon, extinction of
craving gradually followed. Relapse caused by classically conditioned craving and
withdrawal had previously been extensively described in opiate and nicotine withdraw-
al, so their appearance in cocaine abuse was unsurprising. The clinical impression we
formed, however, was that evoked cocaine craving was more intense than that
occurring with other commonly abused substances, a not unexpected finding given
cocaine's extreme potency as a reinforcer in animal models, and the established linkage
in animal experiments between strength of reinforcement and magnitude of classical
conditioning. This finding led to a substantial appreciation of the importance of
managing such cues, and to a focus on techniques to attenuate safely the potency of
such cues in psychotherapy treatment and research efforts (reviewed below).
Psychiatric Co-Morbidity [7,8]
Weiss and colleagues [21-22] at MacLean Hospital conducted research on
psychiatric disorder in inpatient cocaine abusers at the same time that we conducted
similar studies in outpatients at Yale [7,20]. Research from both groups indicated that
DSM-III Axis I interview timing and application had to be modified when applied to
cocaine abuse and that, while some cocaine abusers suffer primarily from an addictive
disorder, substantial proportions might be self-medicating psychiatric disorders such
as depression.
Modification of interview timing was needed because "crash" symptoms mimic
those of depressed states in affective disorders. In the diagnostic studies cited,
DMS-III criteria were applied but clinical assessments were delayed, until crash
symptoms should have abated, before diagnostic assessments took place. Significantly,
application ofthis delay resulted in acceptable diagnostic validity [21].
In the two sets oftwo studies done by Weiss et al. [21,22] and ourselves [7,8], Axis I
affective disorders were present in 30-50 percent of cocaine abuse treatment-seeking
populations, and attention-deficit disorder-residual type (ADD-RT) was present in
3-5 percent. These findings suggested significant implications regarding predisposi-
tion to cocaine abuse. Anxiety or panic disorders and schizophrenia were almost
absent, indicating that dysphoric effects of cocaine in these populations may select
against the development ofabuse. Conversely, the prevalence ofcyclical mood disorder
(cyclothymic disorder and bipolar disorder) may be ten times higher in cocaine abuse
treatment populations compared to opiate and alcohol abuse populations, suggesting
preferential selection for cocaine in such individuals.
It should be noted that, because of the coexistence of chronic cocaine abuse, it is
impossible to be certain whether these disorders represented pre-abuse psychopatholo-
gy, psychopathology exacerbated by cocaine, or cocaine-induced disorders. Similarly,
the permanence of such states during long-term abstinence has not yet been
determined. But, regardless of uncertainties over etiology or stability, the observation
of diagnostically discrete sub-populations in cocaine abuse treatment populations has
led to important clinical assessments of appropriate pharmacotherapies. In turn,
remarkable amelioration of cocaine abuse has been reported in cyclical and attention-
deficit disorder cocaine abusers treated appropriately with, respectively, lithium and
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stimulant medications, while no response to these agents is found in cocaine abusers
without these diagnoses (reviewed in [16]).
Continuing and Future Research on the Clinical Phenomenology ofCocaine Abuse
The studies reviewed created a foundation for investigation of cocaine abuse that
helped clarify essential clinical research questions to be addressed in further, more
rigorous studies and future research. Numerous investigators are currently examining
the clinical characteristics of cocaine dependence. In studies now under way, we and
colleagues are evaluating: (1) distinctions between cocaine users who have not sought
treatment and those in our treatment programs, in order to learn about potential
factors creating the transition to dependence and creating the motivation to seek
treatment; (2) the range of abuse patterns and their development, in order to quantify
severity and potentially to predict prognosis, as well as to facilitate development of
accurate animal models of cocaine dependence (discussed below); (3) whether cocaine
abstinence symptoms are amenable to structured, systematic assessment; the findings
reviewed thus far have been substantiated by other clinical impressions reported by
other investigators but have not yet been subject to structured research evaluations.
Investigations are under way that will assess symptom expression in research hospital
wards after experimental administration of cocaine. Both behavioral (e.g., ratings of
withdrawal symptoms by blind raters) and neurochemical indices of cocaine with-
drawal are being investigated. Furthermore, the application of new instruments
developed for other psychiatric disorders (such as anhedonia scales developed for
depression) to cocaine abusers is being assessed in clinical studies. (4) Factors that
influence the time course and intensity of abstinence symptoms, such as total cocaine
abuse history, recent use, co-use of other substances, and Axis I co-morbidity, are also
being assessed in clinical studies. (5) The interrelationship of anhedonic craving for
cocaine and craving evoked by cues is being explored. In opiate abuse, cues have been
demonstrated to evoke not only a desire for opiate euphoria, but also withdrawal
symptoms which in turn superimpose additional desire for opiates in order to relieve
these symptoms. Whether cocaine cues can evoke or worsen anhedonia, in addition to
provoking desire for cocaine euphoria, remains to be assessed.
EVOLVING APPLICATIONS OF PRE-CLINICAL RESEARCH TO
CLINICAL PROBLEMS
When our studies began, it was assumed that neuroadaptation did not occur in
human cocaine abuse and that cocaine was only "psychologically" addicting. Nonethe-
less, the brain's prototypical response to persistent, drug-induced neurochemical
perturbation is homeostatic compensatory neuroadaptation. We consequently evalu-
ated available pre-clinical data to determine if the abstinence symptomatology we
observed might be based in neurophysiological adaptations to chronic cocaine adminis-
tration.
Substantial pre-clinical research (reviewed in [23-25]) had established that cocaine
and amphetamine facilitate activity of a central nervous system reward system,
presumably by increasing neurotransmission in mesolimbic and/or mesocortical
dopaminergic tracts. In humans, activation of these pathways would produce sensa-
tions of euphoria. Lesions in these pathways block cocaine effects in animal experi-
ments. Dopamine receptor blockers, which should disrupt transmission in these
pathways, also attenuate cocaine effects in animals. Furthermore, electrical self-
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stimulation using electrodes placed in these pathways produces behavior identical to
that observed in cocaine self-administration experiments.
Although less pre-clinical research on chronic cocaine administration had taken
place than on acute cocaine effects, most reports described neurophysiological
alteration from chronic administration ofcocaine or the very similar abused stimulant,
amphetamine. A crucial concordance existed between animal models of pleasure and
our clinical observations ofcocaine withdrawal. Intracranial electrical self-stimulation
(ICSS) in animals, of the same dopaminergic reward pathways that are activated by
acute cocaine administration, had previously been used as a model for human pleasure.
Chronic stimulants decrease ICSS reward indices (reviewed In [11]). These ICSS
decrements implied that chronic cocaine abuse could produce a neurophysiological
downregulation of the brain reward regions activated by acute cocaine use. Such
downregulation would be consistent with our clinical observations of protracted
anhedonia in abstinent stimulant abusers. Complementary findings existed in neurore-
ceptor adaptation studies. Central dopaminergic, a-adrenergic, and fl-adrenergic
receptor supersensitivity were demonstrated after chronic cocaine administration
(reviewed in [26]), but pre-synaptic and post-synaptic receptor changes were not
differentiated in these studies. We hypothesized that relative autoreceptor supersensi-
tivity would decrease dopaminergic neurotransmission and might provide a foundation
both for the ICSS changes demonstrated in animals and the anhedonia observed in
humans [7].
The concordance ofclinical and pre-clinical data provided a foundation for the new
hypothesis that clinical cocaine dependence was associated with sustained neuro-
physiological changes, but in brain systems that regulate only psychological
processes-particularly, hedonic responsivity or pleasure-and therefore involved a
true physiological addiction and withdrawal, but one whose clinical expression
appearsprimarily psychological.
Despite the compelling concordance and parsimony of generalizing between pre-
clinical findings and clinical findings on cocaine, the existence of a neuroadaptive
withdrawal state in cocaine abusers remains a not yet proven working hypothesis.
Before this hypothesis can be considered proven or disproven, not only will broader
investigations of cocaine's consequences be needed, but also advances in research
methodology: in particular, two fundamental research areas, both the foci of ongoing
work, will require exploration.
The first area of investigation concerns whether the administration conditions in
animal studies generalize to human abuse. Prior chronic animal paradigms have
employed administration patterns that do not reflect human abuse patterns [27]. The
chronic stimulant studies in animals involve daily intraperitoneal drug administration
that may not accurately reflect the consequences of multi-dose binges and the
multiple-day, cocaine-free intervals that characterize human abuse. Administration
duration is also usually only one to three months in such experiments and may not
accurately reflect the consequences of multiple years of cocaine abuse. Hence, more
accurate reproductions of human drug self-administration are needed in future
pre-clinical research.
Second, does evidence of neuroadaptation exist in human beings who abuse cocaine?
While we [9,28] and others [18,29] have conducted studies of neuroendocrine indices
and neurotransmitter metabolite levels, as indices of dopaminergic function, that
appear to be consistent with animal data, such indirect peripheral indices can be
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confounded by multiple sources. For example, other drugs abused, altered sleep cycles,
concurrent medical or psychiatric disotder, and diet might all alter peripheral indices
of central neurotransmitter function, as might duration of abstinence, intensity of
abuse, and genetic heterogeneity, among many others [9]. These confounds caused by
differences in antecedent history can, at present, only be resolved by chronic cocaine
studies in animals that control for all variables other than cocaine administration.
Advances in imaging, particularly in vivo imaging of humans, may soon obviate the
problems ofexamining animals or peripheral indices in humans, bydirectly evaluating
metabolism and neurochemistry in the brains ofcocaineabusers. Thespatial resolution
of current positron efmission tomographic scanning and magnetic resonance spectro-
scopic imaging are currently insufficient to demarcate brain function in the dopamin-
ergic reward regions ofprincipal interest in cocaine abuse studies, but rapid advances
in these imaging technologies may make such studies possible in the near future.
Preliminary imaging studies ofcocaine abusers in withdrawal have already been done
[30,31].
Finally, future research supporting the hypothesis of a neuroadaptive withdrawal
state should also be able to quantify the extent of neuroadaptation. Our preliminary
clinical observations indicate that both symptom severity and duration were related to
the length and intensity of the preceding chronic abuse. Predisposing psychiatric
disorders also amplified withdrawal [7]. Conversely, in infrequent "recreational"
cocaine users without psychiatric disorders, withdrawal may not occur. High-intensity
"binge" cocaine use and coinciding neuroadaptation might be required before with-
drawal occurs. Basic research is thus needed to determine how to "stage" neurophysio-
logical alterations produced by cocaine abuse, and to determine the extent to which
inter-individual differences exist in susceptibility to and recovery from cocaine
neuroadaptation. Such information would aid in providing a precise scientific founda-
tion for a cocaine abuse treatment design.
EVOLVING TREATMENT STRATEGIES
As cocaine abusers began to appear for treatment throughout the United States,
available drug treatments, usually alcohol or opiate abuse psychotherapies, were
applied without adaptation for the unrecognized specific problems, such as anhedonia
or conditioned craving, in cocaine dependence [5,32].
Cocaine abuse treatment, like other substance abuse treatment, can be subdivided
into two phases, abstinence initiation and relapse prevention. These correspond to the
withdrawal and extinction phases ofcocaine abstinence [27].
Abstinence Initiation Strategies
Continued cycles ofstimulant binges or ofdaily use are likely as long as anergic and
anhedonic symptoms are present. Hospitalization, group and individual psychothera-
py, and treatment contracts involving aversive contingencies for continued drug use
have long been employed to facilitate abstinence invaried substance abuse populations
and have been routinely employed in cocaine abuse treatment. Of these, only
hospitalization has the advantage of ensuring abstinence. Hospitalization, however,
also has the simultaneous disadvantage of isolation from the cue-rich environment,
precluding extinction during an inpatient stay.
We and others considered these approaches either inadequate or too costly and
sought new alternatives to treatment ofcocaine anhedonia, exploring pharmacological
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treatments aimed at reversing the hypothesized deficits in dopaminergic reward
systems.
Anhedonia is a common symptom in multiple psychiatric disorders, especially
unipolar and bipolar depression. Tricyclic antidepressants (TCAs), while having broad
effects on numerous depressive symptoms, also effectively reverse the anhedonia of
severe depression. While only 10 percent ofcocaine abusers in treatment samples met
criteria for severe depression, most cocaine abusers report anhedonic symptoms, and
we reasoned that such agents might have specific anti-anhedonic effects in this
population. Pre-clinical data strengthened this possibility. Chronic TCA effects on
neurophysiology are generally opposite to those of chronic cocaine: they induce
receptor subsensitivity rather than supersensitivity. In particular, TCAs produce
autoreceptor subsensitivity in dopaminergic systems and increase dopaminergic trans-
mission, which would oppose the dopaminergic autoreceptor supersensitivity we
hypothesized to underlie cocaine anhedonia. More important, in a little-noticed study
done in 1974, Simpson, investigating whether stimulant-induced ICSS deficits might
provide a useful model for severe depressive disorders, demonstrated that chronic
desipramine treatment increased sensitivity to electrical stimulation in ICSS animals
pre-treated with stimulants, thereby reversing the chronic effect ofthe stimulants [33].
The same findings were later extended to other closely related tricyclic antidepressants
[34]. These results had implications not only as a model for affective disorder but also
had direct implications for stimulant abuse treatment. Regardless of whether autore-
ceptor changes in dopaminergic tracts are responsible for ICSS changes and their
reversal by TCAs, or some other mechanism, is responsible, these data implied that
cocaine anhedonia could be reversed by TCAs.
Despite the presence of significant suggestive animal data from electrophysiology
and neurochemistry research, a decade passed before clinicians began to explore the
possible utility of tricyclic antidepressants in human stimulant abusers. Shortly after
establishing the cocaine clinic in 1982, we began a series of pharmacotherapy pilot
trials in cocaine abusers. In addition to evaluating the efficacy of a TCA, desipramine,
we studied two other agents. Methylphenidate was evaluated because ofthe possibility
that it might rapidly restore dopaminergic reward functioning, analogous to metha-
done treatment for heroin abusers, and lithium was evaluated because of anecdotal
accounts that it had benefitted some stimulant abusers.
The first two trials were open-label comparisons. Subjects in both open trials were
psychotherapy-resistant, outpatient cocaine abusers. The first study [26] compared
desipramine plus psychotherapy, lithium carbonate plus psychotherapy, and psycho-
therapy alone in chronic cocaine abusers who had failed to stop cocaine abuse with the
help of psychotherapy alone. Six desipramine patients (200 mg/day) uniformly
decreased and ultimately ceased their cocaine use during the 12-week trial. Craving
did not change from pre-treatment until the third weekofpharmacotherapy, consistent
with the delayed efficacy ofTCAs in depression and the delay before receptor changes
take place in TCA animal studies [35]. By the end of week three, craving scores were
reduced to one-third of their pre-treatment value. Declines in cocaine use paralleled
thecraving scores. Decreases in useandcraving occurred regardless ofothercoexisting
psychiatric disorders. Subjects without depressive disorders appeared to benefit from a
subtle but consistent increase in the ability to respond to pleasurable stimuli.
Desipramine was uniformly well-tolerated. In addition to these six patients who were
being studied in the formal pilot trial, we reported on an additional six cocaine abusers
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treated with desipramine, and the results were essentially the same. Taken collectively,
the pilot study found that desipramine decreased cocaine craving and resulted in
abstinence in 11 out of 12 chronic cocaine abusers (92 percent).
All of the subjects being treated with psychotherapy alone reported persistent
subjective cravings for cocaine. Only one of the six (17 percent) was able to abstain
totally from cocaine, and only half the group showed any improvement. Six patients
received a combination of lithium plus psychotherapy. Only subjects with cyclothymic
disorder became abstinent in this group.
We continued evaluating TCAs in a second open pilot trial [8,36] in which the
subjects consisted only of individuals without diagnoses of affective disorders, in order
to assess further whether TCA responses occurred in subjects who did not meet criteria
for depression. Twenty-six patients without major affective disorders were selected.
The methods employed were otherwise the same as in the first trial. Six patients
declined pharmacotherapy and were used as a non-medication comparison group.
Open pharmacological treatment was added to the psychotherapy treatment regimen
in the remaining 20 patients, who were randomly assigned to desipramine, or a
comparison active treatment (lithium or methylphenidate).
Desipramine hydrochloride produced abstinence in over 80 percent of a desipramine
group, compared to less than 40 percent in comparison groups who were given other
agents (lithium and methylphenidate) or continued in psychotherapy without medica-
tion. As in our first study, craving and cocaine use decreased in the desipramine group
after a typical tricyclic time lag. Methylphenidate produced rapid reductions in
craving during the first week that then reversed. As methylphenidate tolerance
developed, subjects described conditioned craving as a result of mild methylphenidate
stimulation. The methylphenidate trial was stopped after five subjects had been
treated for four weeks because all five deteriorated clinically [37]. Subsequent subjects
were given lithium.
Similarly promising results occurred in an independent, simultaneous open trial in
an unselected population using another tricyclic, imipramine, conducted by Rosecan
and colleagues [38]. Tennant and colleagues [39] assessed short-term, low-dose
desipramine courses, which do not produce the neurophysiological changes of longer
courses [35], and found that these did not facilitate abstinence. By 1985, four groups
had reported open-trial data that TCAs facilitated recovery from cocaine abuse.
These promising early results led to a substantial effort to evaluate these findings
using double-blind methods. Gianinni et al. recently completed the first double-blind
trial in 24 cocaine abusers, contrasting desipramine to an active placebo, diphenhy-
dramine [40]. Ongoing, double-blind, placebo-controlled studies by ourselves and
O'Brien et al. have also reported mid-point data; these investigations have confirmed
that desipramine produces statistically and clinically significant increases in absti-
nence rates [36,41] and decreases in cocaine use, craving, and symptom scores
[36,40-41].
While these findings remain tentative, since two of the studies require completion,
they imply that a generally effective pharmacotherapy to facilitate abstinence
initiation exists. Three additional groups have recently initiated double-blind TCA
trials, and a complete assessment of the value of TCAs in the abstinence initiation
phase ofcocaine abuse treatment will shortly exist. If proven effective by this collective
research, an extremely important, new, effective, inexpensive, and expedient modality
for cocaine abuse treatment will be available for the first time.
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Other experimental pharmacological research strategies, all based on a rationale of
increasing reward transmission in dopaminergic reward systems, are also in prelimi-
nary stages of investigation. Most are attempts to increase dopaminergic neurotrans-
mission directly using dopamimetic agents like amantidine [42], bromocriptine [43],
tyrosine [44], and, as described above, methylphenidate [37]. These agents have all
been reported to produce acute decreases in cocaine craving in small, short-term open
trials, lending further substantiation to the hypothesis that cocaine produces a
neuroadaptation that can be affected pharmacologically. The clinical utility of these
treatments, however, is less clear than for TCAs. Tennant and colleagues conducted a
double-blind comparison ofamantidine and bromocriptine in 14 cocaine abusers [42],
but 71 percent of the bromocriptine subjects dropped out because of side effects,
rendering the amantidine findings difficult to interpret. Giannini has reported
double-blind reductions in symptom scores in bromocriptine-treated subjects com-
pared to those given placebo but did not report abstinence or craving data.
Relapse Prevention Strategies
While relapse prevention pharmacotherapies exist for opiate and alcohol abuse
(naltrexone and disulfiram, respectively), no similar pharmacotherapy has yet
emerged for cocaine dependence (possible stimulant blockade has also been tried using
lithium [26], trazodone [45], imipramine, and neuroleptics [25], but these experiments
have not yet demonstrated a clinically useful blockade of cocaine effects for any
pharmacotherapy).
Beginning studies are now under way in our treatment programs to elucidate which
psychotherapeutic techniques best preclude relapse in cocaineabusers. The approaches
under study are generally comparable to those used after withdrawal in other
substance abuse treatments [46]. The goal of relapse prevention is gradually to
decrease the external controls placed on the abuser, by family and therapist, during
initiation ofabstinence, and gradually tofacilitate development ofthe abuser's internal
controls. Relapse prevention techniques include extinguishing conditioned cues, reduc-
ing external dysphoria and stress, developing drug-free socialization networks, pre-
dicting situations of high relapse risk, rehearsing avoidance strategies, and connecting
memories ofnegative consequences ofcocaine abuse to positive memories ofcocaine in
order to counteract evoked memories of cocaine euphoria. Idiosyncratic needs in the
addict's life that the stimulant may have met, albeit dysfunctionally, are also explored
and constructive alternatives to meeting these needs are pursued [47].
While conceptually attractive and clinically expedient, such techniques have not yet
been systematically evaluated. Using precisely applied, research psychotherapy meth-
odologies, fundamental questions are now being assessed as to whether systematic
application of these straightforward relapse prevention techniques improves outcome
compared to less directive psychotherapy. Examples of questions being addressed by
current studies include: (1) What is the relative value ofeach ofthe relapse techniques
listed above? (2) Can internal cues (e.g., those evoked by mood states or interpersonal
strife) be extinguished as readily as external cues (e.g., locations where cocaine was
used) that are more easily reproduced and controlled? (3) When should return to the
cue-rich environment be avoided, and when should it be advocated? (4) Do such
treatments have additive or interactive effects when combined with pharmacothera-
pies? While this research is in its infancy, it promises guided, rational application of
psychotherapy to prevent relapse.
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CONCLUSION
The advent of cocaine dependence as a drug-dependence disorder without gross
physiological withdrawal symptoms forces reconceptualization of"classic" drug abuse
constructs such as dependence, tolerance, and withdrawal. These constructs have been
based on gross physiological measures and have been unchanged for decades. There
exist for benzodiazepines, alcohol, and opiates excellent anti-withdrawal agents that
reverse gross physiological withdrawal symptoms, but these agents have not solved the
problem of addiction to these drugs. This implies that other symptoms contribute to
unrelenting abuse. These symptoms may be of the same order as the psychological
symptoms expressed in cocaine withdrawal and may also be neurophysiological in
origin. The lack of broad clinical applicability of "classic" constructs of withdrawal,
tolerance, and dependence based on gross physiological parameters has led the World
Health Organization to discard old terms in favor of the more physiologically precise
"neuroadaptation" [48], and recently led the American Psychiatric Association to
define drug dependence in behavioral rather than gross physiological terms for the first
time [49].
The concept of cocaine dependence has evolved, within one decade, from a
non-existent disorder to a complexly regulated disorder with interwoven behavioral,
psychological, and neurophysiological components. It is unlikely that a shift ofsimilar
magnitude will result from our or other's research efforts during the next decade;
instead, future research, at Yale's cocaine abuse clinic and elsewhere, will provide
increasingly precise depictions of the details of the development, expression, and
management ofcocaine abuse.
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